Please assess the completion status of the following clinical trial:

Trial Title: JSP191 (Briquilimab) in Subjects With LR-MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* MDS with IPSS-R very low, low, or intermediate risk features~* Symptomatic cytopenias~* Women of childbearing potential (WOCBP) must agree to use an oral or implanted contraceptive, a double-barrier method of birth control, or an intrauterine device upon enrollment and through 3 months after receiving the last dose of JSP191~* Women not of childbearing potential must be post-menopausal (no menstrual period for a minimum of 12 months) or surgically sterilized and have a negative serum pregnancy test upon study entry~* Male subjects must be surgically sterile or willing to use contraception upon enrollment and through 3 months after receiving the last dose of JSP191~* Must be willing and able to provide informed consent~Exclusion Criteria:~* Anemia secondary to iron deficiency, vitamin B12 deficiency, or folate deficiency~* Prior allogeneic or autologous stem cell transplant~* Known history of human immunodeficiency virus (HIV) (no laboratory testing is required), or active infection with hepatitis B or hepatitis C~* Pregnant women or women who are nursing and do not wish to discontinue breastfeeding~* Any other medical condition that, in the opinion of the Investigator, could pose a significant safety risk to the subject or jeopardize the integrity of the study~* Subjects who, in the opinion of the Investigator, may not be able to comply with the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JSP191 (Type: EXPERIMENTAL): This study will explore up to 5 ascending dose levels (Cohorts 1, 2, 3, 4, and 5) and subjects will receive JSP191 on Day 1 on each 8-week cycle for 4 consecutive cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).